The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.

Key Takeaways The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns.The moves came as one patient who took the combination shot reported nerve damage.